Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Harmony Biosciences’ filings means wading into pages of clinical trial tables, FDA correspondence, and royalty math. If tracking WAKIX revenue trends or matching orexin pipeline milestones to cash runway feels overwhelming, you’re not alone. Harmony Biosciences SEC filings explained simply is exactly what most investors search for—and what Stock Titan delivers.
Our platform adds AI context to every document the moment it appears on EDGAR. The latest Harmony Biosciences quarterly earnings report 10-Q filing is paired with sentence-level summaries that highlight net product sales, R&D spend, and upcoming Phase 3 readouts. A 300-page Harmony Biosciences annual report 10-K simplified shows side panels with trend graphs, while each Harmony Biosciences 8-K material events explained note spells out why an FDA Fast Track designation or safety update matters. Need governance data? The Harmony Biosciences proxy statement executive compensation section links pay packages to regulatory milestones so you can judge incentive alignment in minutes.
Compliance watchers rely on our real-time alerts for Harmony Biosciences Form 4 insider transactions real-time; one click reveals Harmony Biosciences insider trading Form 4 transactions alongside historical charts. Questions like “understanding Harmony Biosciences SEC documents with AI” or “Harmony Biosciences earnings report filing analysis” are answered through concise dashboards that connect filings to market impact. You can even export the full log of Harmony Biosciences executive stock transactions Form 4 for pattern analysis. With comprehensive coverage, AI-powered summaries, and instant access to every form type, Stock Titan turns dense biotech disclosure into clear, actionable insight.
Harmony Biosciences (HRMY) reported strong Q3 2025 results. Net product revenue reached $239,455, generating gross profit of $179,805 and operating income of $65,487. Net income was $50,865, with diluted EPS of $0.87 on 58,717,910 weighted-average diluted shares.
R&D expense rose to $54,962 as the company advanced programs, while sales and marketing and G&A were $29,549 and $29,807, respectively. Cash and cash equivalents were $646,999, and total cash, cash equivalents and investments were $778,412 as of September 30, 2025. Long-term debt principal stood at $170,000 with a 2028 maturity schedule. The company triggered a $15,000 CVR payment tied to a Zynerba milestone, payable in Q4 2025. As of October 31, 2025, 57,596,358 common shares were outstanding. The ANDA settlements allow licensed generic entry beginning January 2030, or earlier under certain circumstances.
Harmony Biosciences (HRMY) filed an 8-K announcing it furnished a press release with financial results for the quarter ended September 30, 2025 and posted an updated investor presentation. The materials are included as Exhibits 99.1 and 99.2 and are provided under Regulation FD.
The company states these exhibits are furnished and not deemed filed under Section 18 of the Exchange Act, and may be used in presentations to investors and analysts. Forward‑looking statements are subject to the risk factors described in prior SEC filings.
Harmony Biosciences (HRMY) announced preliminary net product revenue for the third quarter of 2025 and updated its 2025 net product revenue guidance. The company furnished these details in a press release attached as Exhibit 99.1.
The disclosure falls under Results of Operations and Financial Condition and includes standard forward‑looking statement language.
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported transactions dated 09/30/2025. He acquired 45,000 shares upon vesting of restricted stock units (RSUs) granted on 10/04/2023, and a portion of those shares were withheld to satisfy income tax withholdings as noted. Separately, he disposed of 24,039 shares at a price of $27.56 per share, leaving him with 20,961 shares beneficially owned after the sale. The RSUs vest on a schedule: 40% vested on 09/30/2024, and 30% vest on each of 09/30/2025 and 09/30/2026. The filing was signed by an attorney-in-fact on 10/02/2025.
Harmony Biosciences (HRMY) Form 4: Valor IV Pharma Holdings, LLC reported an in-kind pro rata distribution on 08/28/2025 that disposed of 6,618,033 shares of Harmony common stock without consideration, leaving 0 shares directly owned by Valor IV Pharma Holdings following that transaction. The filing lists remaining indirect holdings across related Valor entities and individuals totaling specific lots of 29,497, 437,619, 50,423, 38,275 and 23,714 shares, held by Valor Management L.P., Antonio Gracias, AJG Growth Fund LLC, Juan Sabater and Tamal, LLC, respectively. The distribution is described in footnotes as an in-kind pro rata distribution by Valor IV Pharma Holdings, LLC, without consideration. The filing is signed by Valor principals and by directors Antonio Gracias and Juan A. Sabater on 09/02/2025.
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), sold 21,573 shares of the company's common stock on 08/15/2025 under a Rule 10b5-1 trading plan. The transactions were executed at a weighted average price of $36.4983 per share, with individual sale prices ranging from $36.11 to $36.87. After these dispositions, the Form 4 reports 0 shares beneficially owned by the reporting person. The filing notes the sale was made pursuant to an established trading plan and offers to provide, upon request, the number of shares sold at each price within the disclosed range.
Harmony Biosciences Holdings, Inc. (HRMY) filed a Form 144 reporting a proposed sale of 21,573 common shares, representing restricted stock units acquired on 03/29/2023. The sale is to be executed through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $787,630.23 and an indicated approximate sale date of 08/15/2025. The filing shows 57,532,601 shares outstanding and indicates no securities sold by the filer in the past three months. The filer certifies they are not aware of undisclosed material adverse information and discloses the sale is related to previously granted RSUs.
FAQ
What is the current stock price of Harmony Biosciences Holdings (HRMY)?
What is the market cap of Harmony Biosciences Holdings (HRMY)?
